Eli Lilly (LLY) stock is trading near its all-time highs ... They've gotten the green light from the FDA for some important new drugs, like Kisunla for Alzheimer's - which is now being used clinically ...

The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to ...

The "Global Drug API Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The global drug API market is projected to reach US$309.642 billion in 2029 from ...

Eli Lilly And Co (NYSE:MRK) revealed new long-term results on Wednesday, showing promise for treatment in patients with ...

Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Indianapolis: Eli Lilly and Company's has announced that the Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

The rate of antipsychotic drug use in nursing homes has remained stubbornly high. Experts are concerned about misuse.

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...